January 23, 2008
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial CancersJanuary 03, 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-December 11, 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem® in Rheumatoid ArthritisDecember 10, 2007
EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia ModelsDecember 10, 2007
EntreMed Presents Results for Its Lead Aurora Kinase-Angiogenesis InhibitorDecember 03, 2007
EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic CancerNovember 06, 2007
EntreMed Reports Third Quarter 2007 Financial ResultsOctober 31, 2007
EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare ConferenceOctober 25, 2007
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198October 25, 2007
EntreMed Shows Increased Survival with MKC-1 in Preclinical Renal Cell Cancer ModelOctober 23, 2007
EntreMed Presents Results for Panzem® NCD Phase 2 Ovarian Cancer StudyOctober 16, 2007
EntreMed Appoints Senior Vice President of Research and DevelopmentOctober 04, 2007
EntreMed to Present at the BIO 2007 Investor ForumOctober 02, 2007
EntreMed Receives Deloitte Technology Fast 50 AwardSeptember 27, 2005
Panzem® Demonstrates Safety and Clinical Benefit in Hormone Refractory Prostate CancerSeptember 15, 2005
EntreMed and the National Cancer Institute Commence Research CollaborationAugust 23, 2005
Disease Modifying Activity of 2ME2 Demonstrated in Preclinical Rheumatoid Arthritis StudiesAugust 17, 2005
New Patents Strengthen EntreMed Position in Cancer and InflammationJuly 28, 2005
EntreMed Reports Second Quarter 2005 Financial ResultsJuly 06, 2005
Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer Models
